Browsing by Author "Kenanoglu O.N."
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Scopus A novel herbal immunostimulant for rainbow trout (Oncorhynchus mykiss) against Yersinia ruckeri(2021-03-01) Terzi E.; Kucukkosker B.; Bilen S.; Kenanoglu O.N.; Corum O.; Özbek M.; Parug S.S.In this 21-day study, we examined the effects of the aqueous methanolic extract of thin-skinned plum (Prunus domestica) on growth, immune response and resistance to a pathogenic bacterium, Yersinia ruckeri in rainbow trout (Oncorhynchus mykiss). Fish were fed with diets containing thin-skinned plum extract doses as 0 (Control) 0.1 (PD01), 0.5 (PD05) and 1% (PD1) ad libitum twice in a day. At the end of the study, growth was affected positively but not significantly. Feed conversion ratio (FCR) was decreased in the PD01 group (P < 0.05). There were elevated respiratory burst and potential bacterial killing activities on the 7th day in the PD1 fish group. No differences were observed in lysozyme activity (P > 0.05). An increased myeloperoxidase activity was recorded on the 14th day of study. Expression of interleukin and COX-2 genes was elevated on the 7th day of study in the kidney and intestine of treated fish. Histological results indicated no marked changes in organs (gill, kidney, liver and spleen) of PD treated fish groups. Challenge results of fish in all plum extract-treated groups showed an increased survival rate against Y. ruckeri (P < 0.05). This study indicated that the thin-skinned plum aqueous methanolic extract could improve innate immunity, survival against Y. ruckeri and decrease the FCR level.Scopus Effects of Greek juniper (Juniperus excelsa) extract on immune responses and disease resistance against Yersinia ruckeri in rainbow trout (Oncorhynchus mykiss)(2021-06-01) Bilen S.; Ispir S.; Kenanoglu O.N.; Taştan Y.; Güney K.; Terzi E.This study investigated the effects of Greek juniper extract on immune responses of rainbow trout. In this experiment, 4 doses [0 (Control), 1 (J1), 4 (J4) and 8 (J8) mg/kg] of the extract were administered orally using an oral gavage twice a day for 14 days. Immune responses were measured on 7th and 14th days. On 14th day, Yersinia ruckeri was injected intraperitoneally to all fish of all groups. On 14th day, ORP in fish of J1 group increased significantly. Lysozyme activity (LA) was increased in J8 group on 7th day (p <.05). On 14th day, a significant decrease was determined in J1 and J4 treatments in LA. Myeloperoxidase activity was significantly decreased in all groups irrespective of sampling times (p <.05). Interleukin (IL)-1β was significantly elevated in fish of J8 group on 7th day. IL-8 increased in fish of J8 and J4 groups on 7th day of the study. IL-12 gene expression was significantly up-regulated in J8 fish group on 7th day, and in J4 fish group on 14th day. Survival rate was higher in J8 treatment compared to the control and other treatments (p <.05). The results suggest that Juniperus excelsa provides protection against Y. ruckeri in rainbow trout.Scopus Pharmacokinetics of danofloxacin in rainbow trout after different routes of administration(2020-04-15) Terzi E.; Corum O.; Bilen S.; Kenanoglu O.N.; Atik O.; Uney K.The pharmacokinetics of danofloxacin was studied in rainbow trout (Oncorhynchus mykiss) after single administration by intravenous (IV), intramuscular (IM) and oral (OR) gavage at a dose of 10 mg/kg and by 10 mg/L bath for 2 h at 11.7 ± 0.8 °C. Furthermore, minimal inhibitory concentrations (MICs) of danofloxacin against a pathogenic strain of Yersinia ruckeri, Pseudomonas spp., and Aeromonas hydrophila were determined. Plasma concentrations of danofloxacin were determined using high-performance liquid chromatograph - UV and further subjected to noncompartmental analysis. Elimination half-lives for IV, IM, OR and bath administration were 25.97 h, 42.43 h, 41.04 h and 40.41 h, respectively. Peak plasma concentrations (Cmax) for IM, OR and bath administration were 3.64 ± 0.12, 2.93 ± 0.23, and 0.36 ± 0.02 μg/mL, respectively. Bioavailability was 105.87% (IM), 96.92% (OR) and 10.09% (bath). MIC values were 0.02 μg/mL for Y. ruckeri, 3.2 μg/mL for Pseudomonas spp., and 8 μg/mL for A. hydrophila at 12 °C. Danofloxacin provides the desired AUC0–24/MIC (≥125) and Cmax/MIC (≥10) values for Y. ruckeri following administration at a dose of 10 mg/kg (L) from all routes administration, whereas inadequate for Pseudomonas spp. and A. hydrophila. This information may help in the use of danofloxacin in rainbow trout, but increasing doses pharmacokinetics with the residue depletion study and clinical studies in infected fish are needed.Scopus Plasma and muscle tissue disposition of enrofloxacin in Nile tilapia (Oreochromis niloticus) after intravascular, intraperitoneal, and oral administrations(2022-01-01) Corum O.; Terzi E.; Durna Corum D.; Tastan Y.; Gonzales R.C.; Kenanoglu O.N.; Arriesgado D.M.; Navarro V.R.; Bilen S.; Sonmez A.Y.; Uney K.The aim of the study was to investigate the plasma and muscle pharmacokinetic of enrofloxacin (ENR) and its active metabolite ciprofloxacin (CIP) in Nile tilapia (Oreochromis niloticus) following single intravascular (IV), intraperitoneal (IP), or oral (PO) administration at 30 ± 1 °C. In this study, 234 healthy Nile tilapia (120–150 g) were used. The fish received a single IV, IP, or PO treatment of ENR at a dose of 10 mg/kg. The plasma and muscle tissue concentrations of ENR and CIP were measured using high–performance liquid chromatography with fluorescence detection and were evaluated using non–compartmental analysis. The elimination half–life, volume of distribution at steady state, and total body clearance of ENR were 21.7 h, 2.69 L/kg, and 0.09 L/h/kg, respectively. The peak plasma concentrations of ENR after IP or PO administration were 6.11 and 4.21 µg/mL at 0.25 and 2 h, respectively. The bioavailability of ENR for IP or PO routes was 78% and 86%, respectively. AUC(0–120)muscle/AUC(0–120)plasma ratios following the IV, IP, or PO administrations were 1.43, 1.49, and 1.07, respectively. CIP was detected after all routes, but the AUC0–last ratios of CIP to ENR were <1.0% for plasma and muscle. ENR was detected up to 120 h following the IV, IP, or PO administrations. The long residence time of ENR after single IV, IP, or PO administration ensured the plasma concentration was ≥1 × MIC for bacteria with threshold MIC values of 0.92, 0.72, and 0.80 μg/mL over the whole 120 h observed. However, further studies are necessary to determine the optimum pharmacokinetic/pharmacodynamics data of ENR for the treatment of infections caused by susceptible bacteria in tilapia.